Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Industry

10 Jun 2022

A Look at Small Pharma’s Year-End Highlights

With a unique DMT trial currently in Phase 2a for major depressive disorder Small Pharma is a company worth keeping an eye on....

By Jason Najum

Finance

9 Jun 2022

A Look at Mydecine’s Company Update

With market conditions making 2022 a dangerous year for smaller-cap companies, we’re on the lookout for updates on how firms like Mydecine are managing this period of rocky waters....

By Jason Najum

Science

6 Jun 2022

New Study Shows Ketamine’s Fast-Acting Effects on Depression

A new study by Northwestern University shows how ketamine works to counter the effects of depression on the brain....

By Jason Najum

Industry

3 Jun 2022

The Top Clinical Trials in 2022

2022 is expected to be a pivotal year, with the psychedelic industry attempting to solidify itself as a commercially viable endeavor....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Law & Politics

26 May 2022

Oregon Activists Lose Vote for Spiritual Psilocybin Use

With places like Oregon being the testing grounds for future models of psychedelic therapy, these kinds of conversations around access and affordability help lay crucial frameworks for others to follow....

By Jason Najum

Industry

20 May 2022

Awakn Life Sciences Completes New Study for Addiction

Awakn Life Science has announced positive results from a new study that uses ketamine for a range of addiction disorders....

By Jason Najum

Industry

19 May 2022

MindMed Releases Phase 1 Trial Results For Opioid Addiction

MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal...

By Jason Najum

Industry, Law & Politics

16 May 2022

Numinus Receives Health Canada Approval For Psilocybin Treatment

Although still mired in red tape and the whims of bureaucratic decisions, Numinus has been approved to provide psilocybin psychotherapy under the Special Access Program....

By Jason Najum

Law & Politics

12 May 2022

US Senators Send Letter Pushing for Psychedelic Research

Two United States Senators have sent a letter to leadership of federal agencies asking for an update and pushing for advancement on research into psychedelics....

By Jason Najum

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.